[Skip to Navigation]
Sign In
Correction
September 30, 2021

Error in the Abstract

JAMA Oncol. 2021;7(11):1729. doi:10.1001/jamaoncol.2021.5290

In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue,1 the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.

References
1.
Kalinsky  K, Hong  F, McCourt  CK,  et al.  Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial.   JAMA Oncol. 2021;7(2):271-278. doi:10.1001/jamaoncol.2020.6741PubMedGoogle ScholarCrossref
×